IP Library Granted Patent US 10,738,093
Granted Patent B2
US 10,738,093 · App. 16/255,287 · Granted Aug 11, 2020

Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining

Inventors: Pei-Yuan Qian (Hong Kong, CN); Yongxin Li (Hong Kong, CN); Zheng Zhong (Hong Kong, CN); Weipeng Zhang (Hong Kong, CN)
Assignees: The Hong Kong University of Science and Technology; China Ocean Mineral Resources R&D Assocation (COMRA)
C07K14/4723A61K38/04A61P31/04C07K14/345A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,738,093
App. No.
16/255,287
Granted
Aug 11, 2020
Kind
B2
Abstract

Pharmacological compositions comprising a cationic nonribosomal peptide (CNRP) or a salt thereof are described. Further, methods of treating a bacterial infection in a subject by administering to the subject a CNRP or a salt thereof are provided.

Claims (8)

1. A pharmaceutical composition comprising a cationic nonribosomal peptide (CNRP) salt, wherein the CNRP comprises a hydrophobic N-terminal fatty acid chain, a linear cationic segment, and a hydrophobic tear peptide or pentapeptide ring, and the salt is:

i) with an acid selected from hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid (TFA), cyclopentanepropionic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-di sulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, lauryl sulfuric acid, and hydroxynaphthoic acid; or

ii) with a base selected from sodium hydroxide, ammonium hydroxide, potassium hydroxide, monoalkyl amine, dialkyl amine, trialkyl amine, and aryl amine.

2. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable carrier or excipient.

3. The pharmaceutical composition of claim 1 , wherein the CNRP is brevicidine (SEQ ID NO: 1) or laterocidine (SEQ ID NO: 2).

4. A method of treating a bacterial infection, comprising administering to a subject in need thereof, the pharmaceutical composition of claim 1 .

5. The method of claim 4 , wherein the bacterium is a Gram-negative bacterium resistant to an antibiotic selected from an aminoglycoside, carbapenem, monobactam, colistin, cephalosporin, penicillin, macrolide, quinolone, sulfonamide/thrimethoprim, and chloramphenicol.

6. The method of claim 4 , wherein the bacterium is a Gram-negative bacterium belonging to a genus selected from Acinetobacter, Actinobacillus, Bordetella, Brucella, Campylobacter, Cyanobacteria, Enterobacter, Erwinia, Escherichia, Franeiscella, Helicobacter, Hemophilus, Klebsiella, Legionella, Moraxella, Neisseria, Pasteurella, Proteus, Pseudomonas, Salmonella, Serratia, Shigella, Treponema, Vibrio , and Yersinia.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2019
From: QIAN, PEI-YUAN; LI, YONGXIN; ZHONG, ZHENG; ZHANG, WEIPENG
To: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY; CHINA OCEAN MINERAL RESOURCES R&D ASSOCIATION (COMRA)
Reel/Frame 048262/0126 →
Continuity (2)
Provisional Application 62621929 · Jan 25, 2018
Related Publication 20190225663A1 · Jul 25, 2019
Cited By (3)
US 12,281,181 US 12,454,552 US 12,496,350